APA (7th ed.) Citation

Domingo-Domènech, E., Pro, B., Illidge, T., Horwitz, S., Trumper, L., Iyer, S., . . . Savage, K. J. (2025). Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: Subgroup analysis of the ECHELON-2 study at 5 years’ follow-up. Blood cancer journal (New York), 15(1), 129-5. https://doi.org/10.1038/s41408-025-01329-2

Chicago Style (17th ed.) Citation

Domingo-Domènech, Eva, et al. "Brentuximab Vedotin Plus Chemotherapy for the Treatment of Front-line Systemic Anaplastic Large Cell Lymphoma: Subgroup Analysis of the ECHELON-2 Study at 5 Years’ Follow-up." Blood Cancer Journal (New York) 15, no. 1 (2025): 129-5. https://doi.org/10.1038/s41408-025-01329-2.

MLA (9th ed.) Citation

Domingo-Domènech, Eva, et al. "Brentuximab Vedotin Plus Chemotherapy for the Treatment of Front-line Systemic Anaplastic Large Cell Lymphoma: Subgroup Analysis of the ECHELON-2 Study at 5 Years’ Follow-up." Blood Cancer Journal (New York), vol. 15, no. 1, 2025, pp. 129-5, https://doi.org/10.1038/s41408-025-01329-2.